M&A Deal Summary |
|
|---|---|
| Date | 2024-10-22 |
| Target | MARGENZA |
| Sector | Life Science |
| Buyer(s) | TerSera Therapeutics |
| Sellers(s) | MacroGenics |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
TerSera Therapeutics is a specialty pharmaceutical company focused on therapeutics to improve patient outcomes. The company was formed to acquire specialty pharmaceutical companies and products with a focus on select physician specialties. TerSera Therapeutics was founded in 2016 and is based in Lake Forest, Illinois.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector (Life Science) | 2 of 2 |
| Type (Divestiture) | 2 of 2 |
| State (Maryland) | 1 of 1 |
| Country (United States) | 2 of 2 |
| Year (2024) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-07-30 |
Lexicon Pharmaceuticals - XERMELO
The Woodlands, Texas, United States Lexicon Pharmaceuticals's XERMELO is an approved oral therapy for carcinoid syndrome diarrhea. It targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells. XERMELO is approved in the United States, the European Union, and certain additional countries for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Carcinoid syndrome is a rare condition that occurs in patients living with mNETs and is characterized by frequent and debilitating diarrhea. XERMELO targets the overproduction of serotonin inside mNET cells, providing an additional treatment option for patients suffering from carcinoid syndrome diarrhea. |
Buy | $159M |
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Life Science |
| Employees | 339 |
| Revenue | 57M USD (2023) |
MacroGenics is a developer of monoclonal antibodies and vaccines in the areas of oncology, autoimmunity, and infectious disease. The Company has an anti-CD3 monoclonal antibody in Phase III clinical development for type 1 diabetes. MacroGenics has a deep pipeline of clinical and preclinical antibodies enabled by its proprietary Fc-engieering and diabody capabilities. MacroGenics was founded in 2000 and is based in Rockville, Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (Maryland) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2024) | 1 of 1 |
